Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study

作者：Thompson Philip A; Levy Vincent; Tam Constantine S; Al Nawakil Chadi; Goudot Francois Xavier; Quinquenel Anne; Ysebaert Loic; Michallet Anne Sophie; Dilhuydy Marie Sarah; Van Den Neste Eric; Dupuis Jehan; Keating Michael J; Meune Christophe; Cymbalista Florence^*

来源：British Journal of Haematology, 2016, 175(3): 462-466.

DOI：10.1111/bjh.14324

• chronic lymphocytic leukaemia
• ibrutinib
• atrial fibrillation

Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 38months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.

• 出版日期2016-11
• 单位河南工业大学